Tuberculosis in kidney transplant candidates and recipients.

Publication date: Sep 18, 2024

Tuberculosis (TB) is the leading cause of infectious mortality and morbidity in the world, second only to coronavirus disease 2019. Patients with chronic kidney disease and kidney transplant recipients are at a higher risk of developing TB than the general population. Active TB is difficult to diagnose in this population due to close mimics. All transplant candidates should be screened for latent TB infection and given TB prophylaxis. Patients who develop active TB pre- or post-transplantation should receive multidrug combination therapy of antitubercular therapy for the recommended duration with optimal dose modification as per glomerular filtration rate.

Concepts Keywords
Coronavirus Antitubercular therapy
Infectious Donor
Kidney Interferon-gamma release assays
Transplantation Isoniazid
Tuberculosis Kidney transplantation
Latent
Rifampicin
Tuberculin
Tuberculosis

Semantics

Type Source Name
disease MESH Tuberculosis
pathway KEGG Tuberculosis
disease MESH morbidity
disease MESH coronavirus disease 2019
disease MESH chronic kidney disease
disease MESH infection
pathway REACTOME Release
drug DRUGBANK Isoniazid
drug DRUGBANK Rifampicin

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *